QuidelOrtho Corporation(QDEL)Earnings, Financials & Key RatiosQuidelOrtho Corporation (QDEL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's fundamental instability is highlighted by a $733.0M net loss in 2025Q3 and a thin cash position of only $140.4M as of 2026Q1, which provides limited protection against ongoing operational deficits.
QuidelOrtho Corporation (QDEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
QuidelOrtho Corporation (QDEL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.04vs $0.37-110.8% | $620Mvs $665M-6.8% |
| Q1 2026 | Feb 11, 2026 | $0.46vs $0.43+7.0% | $724Mvs $701M+3.3% |
| Q4 2025 | Nov 5, 2025 | $0.80vs $0.51+56.9% | $700Mvs $700M-0.0% |
| Q3 2025 | Aug 5, 2025 | $0.12vs $0.56-78.6% | $615Mvs $676M-9.1% |
Recent stock market news and headlines for QuidelOrtho Corporation (QDEL)
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M.
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
On June 16, 2026, QuidelOrtho Corp (QDEL) shares fell 3.3%, bringing the current price to $14.13. The stock has experienced significant volatility, with a 52-we
Key metrics vs top competitors for QuidelOrtho Corporation (QDEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.00 | $1.16B | -1.02 | -1.89% | -41.45% | -46.15% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $292.50 | $7.9B | 10.50 | 0.65% | 6.52% | 2.4% | — | |
| $9.39 | $2.04B | -1.87 | -3.2% | -69.93% | -29% | — | |
| $570.25 | $45.29B | 43.60 | 10.42% | 24.63% | 70.87% | — | |
| $185.22 | $13.26B | 32.78 | 0.9% | 10.5% | 10.7% | — |
QuidelOrtho Corporation (QDEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QuidelOrtho Corporation (QDEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 15, 2026·SEC
Mar 24, 2026·SEC
Get notified when QDEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QuidelOrtho Corporation (QDEL) stock FAQ — growth, dividends, profitability & financials explained
QuidelOrtho Corporation (QDEL) reported $2.66B in revenue for fiscal year 2025. This represents a 7602% increase from $34.5M in 1995.
QuidelOrtho Corporation (QDEL) saw revenue decline by 1.9% over the past year.
QuidelOrtho Corporation (QDEL) reported a net loss of $1.21B for fiscal year 2025.
QuidelOrtho Corporation (QDEL) has a return on equity (ROE) of -46.1%. Negative ROE indicates the company is unprofitable.
QuidelOrtho Corporation (QDEL) had negative free cash flow of $75.2M in fiscal year 2025, likely due to heavy capital investments.
